Close menu

February 7th, 2024 | 07:30 CET

BASF shares on the upswing, BioNTech sees breakthrough in cancer, and Defence Therapeutics benefits from study

  • Biotechnology
  • chemicals
  • Cancer
Photo credits: BASF SE

Can BASF shareholders look forward to better times? One analyst is certainly hopeful. He believes that the chemical industry will recover in 2024. However, the price target gives pause for thought. The development of cervical cancer is also concerning. According to a new study, the number of cases has risen sharply in recent years, and with it, HPV infections. Accordingly, more HPV vaccines are urgently needed. The market volume is expected to more than double to over USD 15 billion in just a few years. Defence Therapeutics aims to become a profiteer. The biotech company is fighting cancer with its Accum™ platform. BioNTech CEO Ugur Sahin also believes that humanity will get cancer under control, thanks in part to artificial intelligence. The Company is currently working on 30 cancer therapies. Is it a good time to invest now?

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Defence Therapeutics: Study reveals potential in the billion-dollar market

    The market for HPV vaccines is expected to grow from USD 6.51 billion in 2022 to USD 15.94 billion by 2028, representing a doubling within just a few years. This conclusion is drawn from a recent study by Stratview Research. Background: Human Papillomaviruses (HPV) are among the most common viruses transmitted through intimate contact. They often result in cancers such as genital and cervical cancer. According to the study, the COVID-19 pandemic has had a significant impact on the spread of HPV. The overwhelmed healthcare systems led to significantly fewer screenings for sexually transmitted diseases. As a result, there are considerably more cases and fatalities, particularly in cervical cancer.

    Defence Therapeutics should benefit from the increasing demand for HPV vaccines. The Canadian biotech company has developed a versatile platform technology, Accum™. The unconjugated Accum™ molecule can be used to fight cancer in two ways. Firstly, by directly inducing cell death in various cancer cell lines (T-cell lymphoma, colon cancer, melanoma and breast cancer). It also works indirectly by "alerting" the affected person's immune system to fight the cancer cells. As a result, cancer and other infectious diseases can be fought efficiently and very effectively. Research into various cancer vaccines is already underway. Defence Therapeutics is currently valued at less than CAD 100 million.

    BioNTech: Defeating cancer with the help of AI

    BioNTech currently has a market capitalization of around USD 22 billion. The share price is currently testing support at around USD 90. Due to declining income from the COVID-19 vaccine and potential revenues from new drugs only in the medium term, the German biotech star is running out of steam. However, CEO Ugur Sahin is confident about the Company's future prospects. In an interview with "Der Spiegel", Sahin sees the field of medicine as well on the way to "controlling or ideally curing cancer in the long term". The BioNTech co-founder believes that digital technologies and artificial intelligence are driving research forward. He, therefore, sees "no fundamental reason why many types of cancer should not be detectable earlier and more effectively treatable." BioNTech itself has already invested in AI specialists in the past. Sahin believes that by 2026, the first drugs should be ready for approval. By 2030, BioNTech should then have an extensive portfolio of cancer therapies. The Company currently has a research pipeline comprising 30 new cancer therapies.

    BASF: Price target raises questions

    For almost two years, BASF's stock has been fluctuating – with a few deviations upward and downward – between EUR 50 and EUR 40. Currently, it is trading at just under EUR 45. The economic sensitivity of the chemical industry has provided little upside potential. However, there are increasing signs that the downturn in the sector is coming to an end. Berenberg has recently expressed a positive outlook. Those who had bet on the upturn in the chemical industry in 2023 should be rewarded in the current year. Volumes and margins are expected to develop positively in 2024. Diversified companies, in particular, should be able to benefit from this. It all sounds positive for BASF and like a "Buy" recommendation. However, analysts cannot bring themselves to that conclusion. For them, BASF shares with a price target of EUR 46 are only a "Hold".

    BASF is currently making negative headlines in another aspect. According to reports from ZDF magazine "frontal" and "Der Spiegel", the chemical company is increasingly involved in the system of oppression against the Uyghur minority in China. According to the report, employees of a joint venture between BASF and a Chinese company made home visits to Uyghur families in 2018/19, conducted investigations, and apparently passed on their findings to state authorities. In some cases, it was reported that the employees even moved in with the families. BASF intends to investigate the allegations.

    The fight against and cure for cancer represents a billion-dollar market - and the trend is still rising. Defence Therapeutics has developed an exciting platform and is building a research pipeline. The valuation is not high, and there are frequent takeover speculations. The Canadians would certainly also be a good fit for BioNTech. The German biotech company not only has a full pipeline but also cash for possible further acquisitions. At BASF there is the lure of a generous dividend, but operationally, there has been little reason for joy in recent years.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.


    Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

    Bayer, Defence Therapeutics, Novavax - Major events

    • Biotechnology
    • Pharma

    The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.


    Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST

    Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list

    • Biotechnology
    • Pharma

    Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.